These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9327888)

  • 21. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.
    Vander Borght T; Kilbourn M; Desmond T; Kuhl D; Frey K
    Eur J Pharmacol; 1995 Dec; 294(2-3):577-83. PubMed ID: 8750721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute and chronic treatment with neuroleptics: similarities and differences in their action on nigrostriatal, mesolimbic, and mesocortical dopaminergic neurons.
    Julou L; Scatton B; Glowinski J
    Adv Biochem Psychopharmacol; 1977; 16():617-24. PubMed ID: 18904
    [No Abstract]   [Full Text] [Related]  

  • 23. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
    Frey K; Kilbourn M; Robinson T
    Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
    Kemmerer ES; Desmond TJ; Albin RL; Kilbourn MR; Frey KA
    Exp Neurol; 2003 Sep; 183(1):81-6. PubMed ID: 12957491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential polarization of serotonin transporters in axons versus soma-dendrites: an immunogold electron microscopy study.
    Tao-Cheng JH; Zhou FC
    Neuroscience; 1999; 94(3):821-30. PubMed ID: 10579573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter.
    Jaber M; Dumartin B; Sagné C; Haycock JW; Roubert C; Giros B; Bloch B; Caron MG
    Eur J Neurosci; 1999 Oct; 11(10):3499-511. PubMed ID: 10564358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration.
    Lu W; Wolf ME
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):137-48. PubMed ID: 9387873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons.
    Clarke PB; Pert A
    Brain Res; 1985 Dec; 348(2):355-8. PubMed ID: 4075093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra.
    Naudon L; Leroux-Nicollet I; Costentin J
    Neurosci Lett; 1994 May; 173(1-2):1-4. PubMed ID: 7523993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrastructural localization of the serotonin transporter in limbic and motor compartments of the nucleus accumbens.
    Pickel VM; Chan J
    J Neurosci; 1999 Sep; 19(17):7356-66. PubMed ID: 10460242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression.
    Schwartz K; Yadid G; Weizman A; Rehavi M
    Brain Res; 2003 Mar; 965(1-2):174-9. PubMed ID: 12591135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GM1 enhances dopaminergic markers in the brain of aged rats.
    Goettl VM; Zhang H; Burrows AC; Wemlinger TA; Neff NH; Hadjiconstantinou M
    Exp Neurol; 2003 Oct; 183(2):665-72. PubMed ID: 14552908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study.
    Augood SJ; Hollingsworth Z; Albers DS; Yang L; Leung JC; Muller B; Klein C; Breakefield XO; Standaert DG
    Neurology; 2002 Aug; 59(3):445-8. PubMed ID: 12177384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.
    Speciale SG; Liang CL; Sonsalla PK; Edwards RH; German DC
    Neuroscience; 1998 Jun; 84(4):1177-85. PubMed ID: 9578404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Ann Neurol; 2002 Jun; 51(6):767-71. PubMed ID: 12112084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
    Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
    J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo imaging of the brain vesicular monoamine transporter.
    Vander Borght TM; Kilbourn MR; Koeppe RA; DaSilva JN; Carey JE; Kuhl DE; Frey KA
    J Nucl Med; 1995 Dec; 36(12):2252-60. PubMed ID: 8523116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs.
    Zucker M; Weizman A; Harel D; Rehavi M
    Neuropsychobiology; 2001; 44(4):187-91. PubMed ID: 11702019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
    Truong JG; Rau KS; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2003 Aug; 474(2-3):223-6. PubMed ID: 12921866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging the vesicular monoamine transporter.
    Frey KA; Koeppe RA; Kilbourn MR
    Adv Neurol; 2001; 86():237-47. PubMed ID: 11553983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.